Business
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical
About this update from Corbus Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Company expanded precision oncology pipeline with in-licensing of CRB-701: a clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical GroupCRB-701 Phase 1 dose escalation study ongoing in patients with advanced solid tumors in China Presented latest CRB-601 anti-αvβ8 mAb pre-clinical data at American Association of Cancer Research (AACR) 2023 annual meeting with IND submission on track for the second half of 2023Expanded Board of Directors with appointment of Yong Ben, MD NORWOOD, Mass., May 9, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\"Corbus\" or the \"Company\"), a precision oncology company, today provided a corporate update and reported financial results for the first quarter of 2023.\n\n \n \n \n \n \n \n\n \n\"During our first quarter we continued our evolution into a precision oncology company, led by the execution of our exclusive licensing agreement for CRB-701, a next generation Nectin-4 ADC,\" said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. \"We are excited about the potential of this differentiated clinical stage asset that targets Nectin-4 enriched tumors. We also presented additional pre-clinical data at AACR 2023 annual meeting on CRB-601, demonstrating robust target engagement associated with anti-tumor activity alone and in combination with anti-PD-1. We believe this data reinforces the potential of this new approach in blocking activation of TGFβ locally in the TME. We look forward to advancing both CRB-701 and CRB-601 and potentially delivering on a number of milestones in 2023.\"\nKey Corporate and Program Updates:\nCRB-701 next generation Nectin-4 ADC:Licensed CRB-701 from CSPC Pharmaceutical Group with exclusive development and commercialization rights in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.Nectin-4 is a clinically validated tumor associated antigen in urothelial cancer. The Nectin-4 ADC PADCEV® (SeaGen/Astellas) is approved for use in late metastatic urothelial cancer and recently received an expanded label from the Food and Drug Administration based on accelerated approval for use in combination with KEYTRUDA® for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.CRB-701 is designe...